Tisagenlecleucel_CellTherapyReleaseQualityChecker
Tisagenlecleucel Cell Therapy Release Checker
ADC Advanced therapy Biopharma BiopharmaExtended Bispecific CSV→JSON CellTherapy FDC
Open selectionTisagenlecleucel Cell Therapy Release Checker — Tisagenlecleucel (CAR-T therapy)
ℹ️ Utility checks critical release parameters of tisagenlecleucel (Kymriah):
• Viability (≥70%)
• % CAR-positive cells (20-60%)
• Total viable CAR+ cells (≥1.0E6)
• % CD3+ T-cells (≥60%)
• B-cell contamination (≤5%)
• Mycoplasma (Negative)
• Endotoxins (≤5 EU/dose)
• Vector copy number (0.5-5.0)
• Potency (IFN-gamma ≥1000 pg/mL)
⚠️ CRITICAL: This is a personalized product! Error is unacceptable.
Mycoplasma or low viability leads to batch rejection.
Usage:
TisagenlecleucelQualityChecker.exe → demo mode (console output)
TisagenlecleucelQualityChecker.exe input.csv output.json → evaluate your data
Input format:
BatchNumber,ViabilityPercent,CARPositiveCellsPercent,TotalViableCARPositiveCells,CD3PositiveCellsPercent,BCellContaminationPercent,MycoplasmaTest,EndotoxinsEUPerDose,VectorCopyNumber,PotencyIFNg_pg_ml,PatientID
Example (mycoplasma: 0=Neg, 1=Pos):
KYM-2026-PAT-001,85.0,45.0,1.5E7,92.0,1.0,0,2.0,2.5,1500.0,PAT-12345
— WHY IS THIS NEEDED?
Tisagenlecleucel (Kymriah) is the first approved CAR-T gene therapy:
• Uses patient's own T-cells modified to attack CD19+ tumor cells
• Used for relapsed/refractory B-cell acute lymphoblastic leukemia (ALL) and lymphoma
• Manufacturing process is individual for each patient (autologous)
• Requires strictest quality control due to risks of cytokine release syndrome and neurotoxicity
⚠️ CRITICAL:
• Viability ≥70% — dead cells do not work and may cause inflammation
• CAR+ cells 20-60% — determines product specificity against tumor
• Dose (cell count) — must be sufficient to achieve remission
• Absence of mycoplasma — absolute safety requirement
• VCN (vector copies) — too high increases oncogenesis risk, too low reduces efficacy
• Potency (functional activity) — confirms cells can kill tumor
Key features:
• Identity check (CAR+, CD3+)
• Purity check (B-cell removal)
• Safety check (mycoplasma, endotoxins, VCN)
• Potency check (functional assay)
• Link to Patient ID (personalized medicine)
Critical parameters:
• Viability: ≥70.0%
• CAR-positive cells: 20.0–60.0%
• Total viable CAR+ cells: ≥1.0E6
• CD3+ cells: ≥60.0%
• B-cell contamination: ≤5.0%
• Mycoplasma: Negative (0)
• Endotoxins: ≤5.0 EU/dose
• VCN: 0.5–5.0 copies/cell
• Potency (IFN-gamma): ≥1000 pg/mL
💡 Usage tips:
1. Analysis performed by Flow Cytometry
2. VCN determined by qPCR
3. Potency measured in co-culture assay with target cells
4. Product stored cryopreserved in liquid nitrogen
5. Any deviation in sterility leads to immediate rejection, as there is no alternative batch for this patient
⚠️ Note: Unlike traditional drugs, CAR-T therapy is a "living drug". Quality depends not only on chemical composition but also on biological activity and cell viability. Each product is unique and intended for only one specific patient.
ℹ️ Utility checks critical release parameters of tisagenlecleucel (Kymriah):
• Viability (≥70%)
• % CAR-positive cells (20-60%)
• Total viable CAR+ cells (≥1.0E6)
• % CD3+ T-cells (≥60%)
• B-cell contamination (≤5%)
• Mycoplasma (Negative)
• Endotoxins (≤5 EU/dose)
• Vector copy number (0.5-5.0)
• Potency (IFN-gamma ≥1000 pg/mL)
⚠️ CRITICAL: This is a personalized product! Error is unacceptable.
Mycoplasma or low viability leads to batch rejection.
Usage:
TisagenlecleucelQualityChecker.exe → demo mode (console output)
TisagenlecleucelQualityChecker.exe input.csv output.json → evaluate your data
Input format:
BatchNumber,ViabilityPercent,CARPositiveCellsPercent,TotalViableCARPositiveCells,CD3PositiveCellsPercent,BCellContaminationPercent,MycoplasmaTest,EndotoxinsEUPerDose,VectorCopyNumber,PotencyIFNg_pg_ml,PatientID
Example (mycoplasma: 0=Neg, 1=Pos):
KYM-2026-PAT-001,85.0,45.0,1.5E7,92.0,1.0,0,2.0,2.5,1500.0,PAT-12345
— WHY IS THIS NEEDED?
Tisagenlecleucel (Kymriah) is the first approved CAR-T gene therapy:
• Uses patient's own T-cells modified to attack CD19+ tumor cells
• Used for relapsed/refractory B-cell acute lymphoblastic leukemia (ALL) and lymphoma
• Manufacturing process is individual for each patient (autologous)
• Requires strictest quality control due to risks of cytokine release syndrome and neurotoxicity
⚠️ CRITICAL:
• Viability ≥70% — dead cells do not work and may cause inflammation
• CAR+ cells 20-60% — determines product specificity against tumor
• Dose (cell count) — must be sufficient to achieve remission
• Absence of mycoplasma — absolute safety requirement
• VCN (vector copies) — too high increases oncogenesis risk, too low reduces efficacy
• Potency (functional activity) — confirms cells can kill tumor
Key features:
• Identity check (CAR+, CD3+)
• Purity check (B-cell removal)
• Safety check (mycoplasma, endotoxins, VCN)
• Potency check (functional assay)
• Link to Patient ID (personalized medicine)
Critical parameters:
• Viability: ≥70.0%
• CAR-positive cells: 20.0–60.0%
• Total viable CAR+ cells: ≥1.0E6
• CD3+ cells: ≥60.0%
• B-cell contamination: ≤5.0%
• Mycoplasma: Negative (0)
• Endotoxins: ≤5.0 EU/dose
• VCN: 0.5–5.0 copies/cell
• Potency (IFN-gamma): ≥1000 pg/mL
💡 Usage tips:
1. Analysis performed by Flow Cytometry
2. VCN determined by qPCR
3. Potency measured in co-culture assay with target cells
4. Product stored cryopreserved in liquid nitrogen
5. Any deviation in sterility leads to immediate rejection, as there is no alternative batch for this patient
⚠️ Note: Unlike traditional drugs, CAR-T therapy is a "living drug". Quality depends not only on chemical composition but also on biological activity and cell viability. Each product is unique and intended for only one specific patient.
input.csv
BatchNumber,ViabilityPercent,CARPositiveCellsPercent,TotalViableCARPositiveCells,CD3PositiveCellsPercent,BCellContaminationPercent,MycoplasmaTest,EndotoxinsEUPerDose,VectorCopyNumber,PotencyIFNg_pg_ml,PatientID KYM-2026-PAT-001,85.0,45.0,1.5E7,92.0,1.0,0,2.0,2.5,1500.0,PAT-12345 KYM-2026-PAT-002,75.0,30.0,8.0E6,85.0,2.0,0,3.5,1.8,1200.0,PAT-67890 KYM-2026-PAT-003,90.0,50.0,2.0E7,95.0,0.5,0,1.0,3.0,2000.0,PAT-11223
Tisagenlecleucel_CellTherapyReleaseQualityChecker — Documentation
Bilingual RU/EN URS & FS. Source:
input.csv and *.description.txt. Package folder: Biopharmaceuticals Extended QC Suite.Utility
Tisagenlecleucel_CellTherapyReleaseQualityChecker
Package
Biopharmaceuticals Extended QC Suite
CSV fields
11
Interface
CSV → JSON
Utility description
Tisagenlecleucel Cell Therapy Release Checker — Tisagenlecleucel (CAR-T therapy)
ℹ️ Utility checks critical release parameters of tisagenlecleucel (Kymriah):
• Viability (≥70%)
• % CAR-positive cells (20-60%)
• Total viable CAR+ cells (≥1.0E6)
• % CD3+ T-cells (≥60%)
• B-cell contamination (≤5%)
• Mycoplasma (Negative)
• Endotoxins (≤5 EU/dose)
• Vector copy number (0.5-5.0)
• Potency (IFN-gamma ≥1000 pg/mL)
⚠️ CRITICAL: This is a personalized product! Error is unacceptable.
Mycoplasma or low viability leads to batch rejection.
Usage:
TisagenlecleucelQualityChecker.exe → demo mode (console output)
TisagenlecleucelQualityChecker.exe input.csv output.json → evaluate your data
Input format:
BatchNumber,ViabilityPercent,CARPositiveCellsPercent,TotalViableCARPositiveCells,CD3PositiveCellsPercent,BCellContaminationPercent,MycoplasmaTest,EndotoxinsEUPerDose,VectorCopyNumber,PotencyIFNg_pg_ml,PatientID
Example (mycoplasma: 0=Neg, 1=Pos):
KYM-2026-PAT-001,85.0,45.0,1.5E7,92.0,1.0,0,2.0,2.5,1500.0,PAT-12345
— WHY IS THIS NEEDED?
Tisagenlecleucel (Kymriah) is the first approved CAR-T gene therapy:
• Uses patient's own T-cells modified to attack CD19+ tumor cells
• Used for relapsed/refractory B-cell acute lymphoblastic leukemia (ALL) and lymphoma
• Manufacturing process is individual for each patient (autologous)
• Requires strictest quality control due to risks of cytokine release syndrome and neurotoxicity
⚠️ CRITICAL:
• Viability ≥70% — dead cells do not work and may cause inflammation
• CAR+ cells 20-60% — determines product specificity against tumor
• Dose (cell count) — must be sufficient to achieve remission
• Absence of mycoplasma — absolute safety requirement
• VCN (vector copies) — too high increases oncogenesis risk, too low reduces efficacy
• Potency (functional activity) — confirms cells can kill tumor
Key features:
• Identity check (CAR+, CD3+)
• Purity check (B-cell removal)
• Safety check (mycoplasma, endotoxins, VCN)
• Potency check (functional assay)
• Link to Patient ID (personalized medicine)
Critical parameters:
• Viability: ≥70.0%
• CAR-positive cells: 20.0–60.0%
• Total viable CAR+ cells: ≥1.0E6
• CD3+ cells: ≥60.0%
• B-cell contamination: ≤5.0%
• Mycoplasma: Negative (0)
• Endotoxins: ≤5.0 EU/dose
• VCN: 0.5–5.0 copies/cell
• Potency (IFN-gamma): ≥1000 pg/mL
💡 Usage tips:
1. Analysis performed by Flow Cytometry
2. VCN determined by qPCR
3. Potency measured in co-culture assay with target cells
4. Product stored cryopreserved in liquid nitrogen
5. Any deviation in sterility leads to immediate rejection, as there is no alternative batch for this patient
⚠️ Note: Unlike traditional drugs, CAR-T therapy is a "living drug". Quality depends not only on chemical composition but also on biological activity and cell viability. Each product is unique and intended for only one specific patient.URS & FS — User Requirements and Functional Specification
This document describes the controlled interface and behaviour of Tisagenlecleucel_CellTherapyReleaseQualityChecker for Tisagenlecleucel Cell Therapy Release Checker.
Portal packages
Biopharmaceuticals Extended QC Suite, Biopharmaceuticals Core QC Suite, Global/API coverage extension, Immunology QC Suite, LabEx QC laboratory utilities, Lumex QC instrument utilities, World API/FDC extension
ADCAdvanced therapyBiopharmaBiopharmaExtendedBispecificCSV→JSONCellTherapyFDCImmunologyMissingAPIOncologyPlasma-derivedQCURS & FSmAbP2Domain limits and critical parameters
Key fragments from the source description are shown below. Before production use, limits must be verified against the approved specification, registration dossier and local SOPs.
- ℹ️ Utility checks critical release parameters of tisagenlecleucel (Kymriah):
- • Viability (≥70%)
- • Total viable CAR+ cells (≥1.0E6)
- • % CD3+ T-cells (≥60%)
- • B-cell contamination (≤5%)
- • Endotoxins (≤5 EU/dose)
- • Potency (IFN-gamma ≥1000 pg/mL)
- ⚠️ CRITICAL: This is a personalized product! Error is unacceptable.
- BatchNumber,ViabilityPercent,CARPositiveCellsPercent,TotalViableCARPositiveCells,CD3PositiveCellsPercent,BCellContaminationPercent,MycoplasmaTest,EndotoxinsEUPerDose,VectorCopyNumber,PotencyIFNg_pg_ml,PatientID
- ⚠️ CRITICAL:
- • Viability ≥70% — dead cells do not work and may cause inflammation
- • Safety check (mycoplasma, endotoxins, VCN)
- • Potency check (functional assay)
- Critical parameters:
- • Viability: ≥70.0%
- • Total viable CAR+ cells: ≥1.0E6
- • CD3+ cells: ≥60.0%
- • B-cell contamination: ≤5.0%
URS — User Requirements Specification
| ID | Requirement | Criticality | Acceptance criterion |
|---|---|---|---|
| URS-001 | The utility shall accept an input.csv file for Tisagenlecleucel Cell Therapy Release Checker with headers defined in the data contract. | High | The file is processed without manual header editing. |
| URS-002 | The utility shall perform deterministic QC evaluation without machine learning and without probabilistic conformance decisions. | High | Identical input data, rule version and configuration produce reproducible results. |
| URS-003 | The utility shall validate mandatory fields, data types, ranges, units and domain plausibility. | High | Schema, conversion and range errors are explicitly reported. |
| URS-004 | The utility shall apply domain limits and rules from the description, approved specification, registration dossier and local SOPs. | High | Each check has PASS/WARNING/FAIL and a clear message. |
| URS-005 | The utility shall generate output.json with machine-readable results, source values, warnings, failures and critical findings. | High | JSON is suitable for LIMS/ELN/MES integration and QA/QC review. |
| URS-006 | The utility shall preserve traceability between batch/sample, input file, applied rules and final status. | High | Output contains identifiers, checked parameters and audit metadata. |
| URS-007 | The documentation shall support IQ/OQ/PQ, CSV/CSA and review by internal QA or inspectors. | Medium | URS, FS, input/output contract and test scenarios are supplied with the utility. |
| URS-008 | The utility shall be used as a QC decision-support tool and not as a substitute for approved specifications and QA/QP release decision. | Medium | Documentation states change control and limit-verification expectations. |
input.csv contract
| # | Field | Type | Sample | Purpose |
|---|---|---|---|---|
| 1 | BatchNumber | string / controlled vocabulary | KYM-2026-PAT-001 | Batch or lot identifier used for traceability. |
| 2 | ViabilityPercent | decimal | 85.0 | Controlled input parameter for deterministic QC rules. |
| 3 | CARPositiveCellsPercent | decimal | 45.0 | Controlled input parameter for deterministic QC rules. |
| 4 | TotalViableCARPositiveCells | decimal | 1.5E7 | Controlled input parameter for deterministic QC rules. |
| 5 | CD3PositiveCellsPercent | decimal | 92.0 | Controlled input parameter for deterministic QC rules. |
| 6 | BCellContaminationPercent | decimal | 1.0 | Controlled input parameter for deterministic QC rules. |
| 7 | MycoplasmaTest | decimal | 0 | Controlled input parameter for deterministic QC rules. |
| 8 | EndotoxinsEUPerDose | decimal | 2.0 | Microbiological/endotoxin parameter relevant to safety. |
| 9 | VectorCopyNumber | decimal | 2.5 | Controlled input parameter for deterministic QC rules. |
| 10 | PotencyIFNg_pg_ml | decimal | 1500.0 | Quantitative content/potency; critical release parameter. |
| 11 | PatientID | string / controlled vocabulary | PAT-12345 | Controlled input parameter for deterministic QC rules. |
BatchNumber,ViabilityPercent,CARPositiveCellsPercent,TotalViableCARPositiveCells,CD3PositiveCellsPercent,BCellContaminationPercent,MycoplasmaTest,EndotoxinsEUPerDose,VectorCopyNumber,PotencyIFNg_pg_ml,PatientID KYM-2026-PAT-001,85.0,45.0,1.5E7,92.0,1.0,0,2.0,2.5,1500.0,PAT-12345 KYM-2026-PAT-002,75.0,30.0,8.0E6,85.0,2.0,0,3.5,1.8,1200.0,PAT-67890 KYM-2026-PAT-003,90.0,50.0,2.0E7,95.0,0.5,0,1.0,3.0,2000.0,PAT-11223
Input validation rules
| ID | Field | Rule | Criticality |
|---|---|---|---|
| VR-001 | BatchNumber | The field shall match an approved dictionary or accepted string representation. | High |
| VR-002 | ViabilityPercent | The value shall be numeric, non-empty and domain-plausible for the approved specification. | High |
| VR-003 | CARPositiveCellsPercent | The value shall be numeric, non-empty and domain-plausible for the approved specification. | High |
| VR-004 | TotalViableCARPositiveCells | The value shall be numeric, non-empty and domain-plausible for the approved specification. | Medium |
| VR-005 | CD3PositiveCellsPercent | The value shall be numeric, non-empty and domain-plausible for the approved specification. | Medium |
| VR-006 | BCellContaminationPercent | The value shall be numeric, non-empty and domain-plausible for the approved specification. | Medium |
| VR-007 | MycoplasmaTest | The value shall be numeric, non-empty and domain-plausible for the approved specification. | Medium |
| VR-008 | EndotoxinsEUPerDose | The value shall be numeric, non-empty and domain-plausible for the approved specification. | High |
| VR-009 | VectorCopyNumber | The value shall be numeric, non-empty and domain-plausible for the approved specification. | Medium |
| VR-010 | PotencyIFNg_pg_ml | The value shall be numeric, non-empty and domain-plausible for the approved specification. | High |
| VR-011 | PatientID | The field shall match an approved dictionary or accepted string representation. | Medium |
FS — Functional Specification
| ID | Function | Implementation |
|---|---|---|
| FS-001 | CLI execution | Support execution modes: demo mode without arguments and production mode input.csv output.json. |
| FS-002 | CSV import | Read input.csv in UTF-8/CSV-compatible format and validate header and expected columns. |
| FS-003 | Schema validation | Check mandatory fields, column count, unknown key fields and empty mandatory values. |
| FS-004 | Type conversion | Convert numeric, flag and text values; invalid format is recorded as a row-level error. |
| FS-005 | Domain rule engine | Apply rules for Tisagenlecleucel Cell Therapy Release Checker, including critical limits from the description and approved specification. |
| FS-006 | Status aggregation | Produce final status: FAIL for critical failure, WARNING for non-critical deviation, PASS for conformance. |
| FS-007 | JSON export | Write output.json with detailed checks, source values, warnings, failures and critical findings. |
| FS-008 | Audit support | Keep result structure suitable for review, deviation investigation and calculation reproduction. |
| FS-009 | Integration contract | Support the scenario LIMS/ELN/MES → input.csv → utility → output.json → portal/admin review. |
| FS-010 | Fallback mapping | For a single API or modality, use this specialized utility together with applicable Lumex/LabEx instrumental checks. |
| FS-011 | Error handling | Return explicit messages for missing file, empty CSV, invalid schema, output write failure and invalid format. |
Example output.json
{
"utilityId": "tisagenlecleucel-cell-therapy-release-quality-checker",
"utilityFolder": "Tisagenlecleucel_CellTherapyReleaseQualityChecker",
"package": "Biopharmaceuticals Extended QC Suite",
"overallStatus": "PASS|WARNING|FAIL",
"sourceFile": "input.csv",
"processedAtUtc": "2026-07-02T00:00:00Z",
"checks": [
{
"parameter": "BatchNumber",
"value": "KYM-2026-PAT-001",
"status": "PASS|WARNING|FAIL",
"message": "Deterministic rule-based check result",
"ruleReference": "FS-RULE-001"
},
{
"parameter": "ViabilityPercent",
"value": "85.0",
"status": "PASS|WARNING|FAIL",
"message": "Deterministic rule-based check result",
"ruleReference": "FS-RULE-002"
},
{
"parameter": "CARPositiveCellsPercent",
"value": "45.0",
"status": "PASS|WARNING|FAIL",
"message": "Deterministic rule-based check result",
"ruleReference": "FS-RULE-003"
},
{
"parameter": "TotalViableCARPositiveCells",
"value": "1.5E7",
"status": "PASS|WARNING|FAIL",
"message": "Deterministic rule-based check result",
"ruleReference": "FS-RULE-004"
},
{
"parameter": "CD3PositiveCellsPercent",
"value": "92.0",
"status": "PASS|WARNING|FAIL",
"message": "Deterministic rule-based check result",
"ruleReference": "FS-RULE-005"
},
{
"parameter": "BCellContaminationPercent",
"value": "1.0",
"status": "PASS|WARNING|FAIL",
"message": "Deterministic rule-based check result",
"ruleReference": "FS-RULE-006"
},
{
"parameter": "MycoplasmaTest",
"value": "0",
"status": "PASS|WARNING|FAIL",
"message": "Deterministic rule-based check result",
"ruleReference": "FS-RULE-007"
},
{
"parameter": "EndotoxinsEUPerDose",
"value": "2.0",
"status": "PASS|WARNING|FAIL",
"message": "Deterministic rule-based check result",
"ruleReference": "FS-RULE-008"
},
{
"parameter": "VectorCopyNumber",
"value": "2.5",
"status": "PASS|WARNING|FAIL",
"message": "Deterministic rule-based check result",
"ruleReference": "FS-RULE-009"
},
{
"parameter": "PotencyIFNg_pg_ml",
"value": "1500.0",
"status": "PASS|WARNING|FAIL",
"message": "Deterministic rule-based check result",
"ruleReference": "FS-RULE-010"
},
{
"parameter": "PatientID",
"value": "PAT-12345",
"status": "PASS|WARNING|FAIL",
"message": "Deterministic rule-based check result",
"ruleReference": "FS-RULE-011"
}
],
"criticalFindings": [],
"warnings": [],
"audit": {
"inputHash": "sha256:<calculated at runtime>",
"rulesVersion": "<utility executable version>",
"documentation": "Tisagenlecleucel_CellTherapyReleaseQualityChecker.documentation.html"
}
}
Traceability matrix
| URS | FS | Test | Evidence |
|---|---|---|---|
| URS-001 | FS-001, FS-002 | OQ-001 | Verify execution and import of valid input.csv. |
| URS-002 | FS-005, FS-006 | OQ-004 | Repeat the same dataset and compare output.json. |
| URS-003 | FS-003, FS-004, FS-011 | OQ-002, OQ-003 | Verify missing columns and invalid types. |
| URS-004 | FS-005, FS-006 | OQ-004, PQ-001 | Verify critical deviations on real/boundary data. |
| URS-005 | FS-007, FS-009 | OQ-005 | Verify JSON schema and downstream-system suitability. |
| URS-006 | FS-008 | OQ-006 | Verify identifiers and audit metadata. |
| URS-007 | FS-008, FS-011 | IQ-001, OQ-007 | Verify documentation completeness and control evidence. |
| URS-008 | FS-005, FS-008, FS-010 | PQ-002 | Verify review workflow and no replacement of QA decision. |
IQ/OQ/PQ test scenarios
| ID | Scenario | Expected result |
|---|---|---|
| IQ-001 | Verify executable, input.csv, documentation and checksum availability. | Delivery set is complete; version is recorded. |
| OQ-001 | Valid sample row from input.csv. | PASS or acceptable WARNING according to rules. |
| OQ-002 | Remove a mandatory CSV column. | Schema error or FAIL with missing-column reference. |
| OQ-003 | Place a non-numeric value into a numeric field. | Type-conversion error with row/field reference. |
| OQ-004 | Set a critical parameter outside the limit. | FAIL and critical finding. |
| OQ-005 | Verify output.json structure. | All mandatory sections are present and JSON is valid. |
| OQ-006 | Verify batch/sample traceability. | Input and result identifiers match. |
| OQ-007 | Verify fallback/decomposition for combined APIs. | Component checks are explicitly documented. |
| PQ-001 | Verify 3–5 real user batches/samples. | Result is confirmed by QC/QA review. |
| PQ-002 | Verify deviation workflow and manual QA decision. | Utility supports review but does not replace approved decision. |
QA/QC and change control
- Do not rename columns without updating validator, documentation and test set.
- Retain input.csv, output.json, executable version and checksum.
- Before production use, perform IQ/OQ/PQ or equivalent CSV/CSA verification.
- Critical limits shall be verified against the approved specification, registration dossier and local SOPs.
- For combination products, document whether the specialized FDC utility or fallback component checks were used.
- The utility provides structured QC decision support; final release decision remains with QA/QP and approved procedures.
Included in packages
Biopharmaceuticals Core QC Suite
Focused QC utility package for biologic products: HCP, mAbs, biosimilars, proteins/peptides, sterility, endotoxins and key release checks.
OpenBiopharmaceuticals Extended QC Suite
Extended QC utility coverage for mAbs, biosimilars, proteins, insulins, vaccines, mRNA/LNP, HCP, sterile release, microbiology, water, cleanroom and stability workflows.
OpenGlobal API & Biosimilars QC Suite
Package for high-demand global APIs, generics and biosimilars, including fixed-dose combinations and biological products.
OpenImmunology QC Suite
QC utility package for immunology: monoclonal antibodies, biosimilars, immunomodulators, immunosuppressants, ELISA/SPR, HCP, protein characterization, sterility and pyrogen/release checks.
OpenWorld API Extension QC Suite
Extended package for 130 additional high-demand APIs and biological products prepared as a market-coverage backlog.
Open